Combine and Conquer: The Integration of Infectious Disease and Addiction Medicine
In this Q&A, Drs Serota and Thakarar discuss the dual subspecialty of infectious disease and addiction medicine and its role in combating the ongoing opioid epidemic.
In this Q&A, Drs Serota and Thakarar discuss the dual subspecialty of infectious disease and addiction medicine and its role in combating the ongoing opioid epidemic.
Sandra Springer, MD, and Laura Marks, MD, PhD, highlight the need for a combined treatment approach for patients with drug-use associated infections.
A study compared clinical characteristics and outcomes between patients with TAVI-IE treated with cardiac surgery and antibiotics and those treated with antibiotics only.
Researchers assessed the effectiveness of the Six Moments of Harm Reduction, an educational tool for clinicians designed to improve knowledge on harm reduction and injection-associated infections.
Investigators conducted a study to assess the incidence and risk factors associated with infective endocarditis in patients with and without active cancer.
In a Q&A, Asher Schranz, MD, MPH, discusses the importance of physician collaboration in the treatment of patients with drug use-associated infective endocarditis.
People with familial hypercholesterolemia with COVID-19 risk endothelial dysfunction. Therapy should continue during the course of the virus.
Researchers conducted a study that compared clinical outcomes and cost-effectiveness of 4 antibiotic treatment strategies for patients with drug-use associated infective endocarditis.
Researchers conducted a study to assess the effects of vancomycin plus ceftaroline for the treatment of patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Researchers sought to determine whether an infectious disease consultation improves clinical outcomes and increases treatment adherence in patients infected with Enterococcus species.